title: Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: A multicenter, randomized, double-blind study. Visipaque in Percutaneous Transluminal Coronary Angioplasty [VIP] Trial Investigators.
abstract: BACKGROUND
  The potential merits and disadvantages of the use of ionic or nonionic contrast media in patients undergoing percutaneous transluminal coronary angioplasty (PTCA) have been the subjects of controversy. The present study was designed to evaluate the possible influence of both types of contrast media on major adverse cardiac events (MACE) in patients undergoing PTCA.
  
  
  RESULTS
  In a randomized, parallel-group, double-blind study, 1411 patients received either iodixanol (a nonionic, iso-osmolar contrast medium) or ioxaglate (an ionic, low-osmolar contrast medium) during PTCA. A standardized anticoagulation regimen was followed. Patients were monitored in the hospital for 2 days and followed-up at 1 month. The primary end point, a composite of MACE (death, stroke, myocardial infarction, coronary artery bypass grafting, and re-PTCA) after 2 days, occurred in 4.3% of the total population, with no statistically significant difference between groups (iodixanol, 4.7%; ioxaglate, 3.9%; P=0.45). Further, between 2-day and 1-month follow-ups, no significant difference (P=0.27) existed between the groups in the rates of MACE. Hypersensitivity reactions (P=0.007) and adverse drug reactions (P=0.002) were significantly less frequent in the iodixanol group. The only significant predicting factors for the occurrence of MACE were dissection/abrupt closure and country.
  
  
  CONCLUSIONS
  No significant differences were observed between the iodixanol and ioxaglate groups with regard to MACE, although hypersensitivity and adverse drug reactions were significantly less frequent in patients who received iodixanol.
authors.affiliation: Division of Cardiology, Lille University Heart Institute, Lille, France. mbertrand@univ-lille2.fr
authors.forename: M E
authors.initials: ME
authors.lastname: Bertrand
authors.forename: E
authors.initials: E
authors.lastname: Esplugas
authors.forename: J
authors.initials: J
authors.lastname: Piessens
authors.forename: W
authors.initials: W
authors.lastname: Rasch
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D003287:Contrast Media / Q000009:adverse effects / Q000627:therapeutic use*; D001026:Coronary Artery Bypass; D004311:Double-Blind Method; D005260:Female; D006331:Heart Diseases / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007430:Intraoperative Care; D007485:Ioxaglic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology; D009994:Osmolar Concentration; D012008:Recurrence; D020521:Stroke / Q000209:etiology; D014283:Triiodobenzoic Acids / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D003287:Contrast Media; D014283:Triiodobenzoic Acids; C044834:iodixanol; D007485:Ioxaglic Acid